Trial Profile

Anti-PD-1 Antibody Sintilimab Combined With Anti-angeogensis Inhibitor Anlotinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy : a Single-arm Prospective Phase II Clinical Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Oct 2023 Status changed from not yet recruiting to recruiting, as per results presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Results (n=30; From July 2021 to February 2023) assessing the efficacy and safety of sintilimab combined with anlotinib and albumin-bound paclitaxel in the treatment of ED-SCLC, presented at the 48th European Society for Medical Oncology Congress.
26 Jul 2021 Planned initiation date changed from 15 Jul 2021 to 26 Jul 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com